Clinical trials in Brno-Zidenice

In Brno-Zidenice, cardiovascular research is strongly represented, with studies focused on heart failure, atrial fibrillation, acute coronary syndromes, hypertension, and broader atherosclerotic cardiovascular disease. These trials are designed to test new treatment options, reduce major cardiovascular events, and improve long-term heart and circulation outcomes.

• Heart failure, including reduced and preserved ejection fraction
• Atrial fibrillation and stroke prevention
• High cardiovascular risk and prevention of major cardiac events
• Evaluating new therapies for better control of symptoms and event reduction

Much of this work aims to improve protection against hospitalization, stroke, and cardiovascular death, while also supporting safer, more effective care for people living with chronic heart conditions.

Clinical trials in digestive system diseases are especially active, covering Crohn’s disease, ulcerative colitis, coeliac disease, and gastroesophageal reflux disease. Researchers are primarily looking at whether new treatments can better control inflammation, promote remission, and improve everyday digestive symptoms.

• Crohn’s disease and ulcerative colitis
• Coeliac disease and intestinal inflammation
• Erosive esophagitis linked to GERD
• Testing therapies aimed at remission, healing, and symptom relief

This area reflects a broad effort to advance both induction and maintenance treatments for inflammatory bowel conditions, as well as better options for upper digestive tract disease.

Immune-focused studies in this city explore conditions such as psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, giant cell arteritis, and polymyalgia rheumatica. The main goal is to understand how new immune-targeted therapies can reduce inflammation, improve mobility, and ease persistent disease symptoms.

• Psoriatic arthritis and axial spondyloarthritis
• Rheumatoid arthritis and related inflammatory joint disease
• Giant cell arteritis and polymyalgia rheumatica
• Assessing immune-modulating treatments for symptom control

These trials support the search for more precise therapies that can calm immune-driven inflammation while helping patients maintain function and quality of life.

Research in musculoskeletal diseases overlaps with inflammatory joint disorders and includes studies in osteoarthritis, juvenile idiopathic arthritis, and related spine and joint conditions. The focus is on easing pain, improving joint function, and finding treatments that can slow disease impact over time.

• Osteoarthritis of the knee and other joints
• Juvenile idiopathic arthritis
• Inflammatory spine and joint disorders
• Evaluating treatments that may reduce pain and improve movement

These studies aim to broaden options for patients whose daily activities are affected by chronic joint inflammation or degenerative joint damage.

Trials in nutritional and metabolic diseases address obesity, overweight, type 2 diabetes, and complications linked to cardiometabolic risk. They are designed to explore whether new approaches can improve weight-related health, lower cardiovascular risk, and support better metabolic control.

• Obesity and overweight
• Type 2 diabetes
• Lipoprotein(a) and other risk-related metabolic factors
• Testing therapies aimed at weight and cardiometabolic improvement

These studies often connect metabolic health with heart protection, reflecting the close relationship between weight, blood sugar, and cardiovascular disease.

In the field of skin and connective tissue diseases, trials are centered on psoriasis and inflammatory conditions that affect both skin and joints. Researchers are evaluating new therapies that may better control visible symptoms while also addressing deeper immune activity.

• Severe chronic plaque psoriasis
• Psoriatic arthritis with skin and joint involvement
• Inflammatory conditions affecting skin and connective tissue
• Assessing treatments for symptom reduction and disease control

These studies highlight the need for therapies that can manage both the physical burden and the long-term inflammatory nature of these conditions.